United Therapeutics: Q3 earnings & TYVASO sales
Q3 results with TYVASO franchise sales in focus. Compare the reported release with prior sales, guidance and company commentary.
United Therapeutics / UTHRPublic biotechEarningsAnnounced: 2026-11-04
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
- The threshold is a prior-quarter reported baseline, not consensus or guidance.
Primary evidence
Company reporting date: 2026-11-04
United Therapeutics announces November 4 earningsPublished 2026-10-21
United Therapeutics Q2 2026 resultsPublished 2026-08-05
United Therapeutics official Q3 results announcementPublished 2026-10-21
Potential outcome market
Will United Therapeutics Q3 2026 total TYVASO revenue exceed $452.6 million?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.